{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:13:00Z","timestamp":1782303180166,"version":"3.54.5"},"reference-count":49,"publisher":"Scientific Scholar","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"\n Aim:<\/jats:title>\n \n To emphasize the feasibility of imaging prostate cancer patients under SPECT\/CT with\n 99m<\/jats:sup>\n Tc-HYNIC-PSMA-11 and evaluate the possibility in clinical application for screening patients for radioligand therapy, with the help of SUV-based biodistribution mapping.\n <\/jats:p>\n <\/jats:sec>\n \n Introduction:<\/jats:title>\n \n In context to prostate specific membrane antigen\u2019s (PSMA) overexpression in prostate cancer cells there has been a gradual increase in imaging prostate cancer, currently the second leading cause of cancer deaths in males and the sixth cause of cancer death worldwide, with the help of radiolabeled PSMA small molecule inhibitors over the past few years. Of the two modalities under Nuclear Medicine facility (positron emission tomography\/CT [PET\/CT] and single photon emission CT [SPECT\/CT]), though PET\/CT has high sensitivity for tumor sites, even at low PSA level less however, the availability of 18F based radiotracer for PET imaging necessitates the dependency on a cyclotron in the near vicinity for production or regular supply. Another option of Germanium 68\/ Gallium 68 generator (\n 68<\/jats:sup>\n Ge\/\n 68<\/jats:sup>\n Ga generator) can be explored but the cost involved becomes a limitation. These challenges led to the exploration of an alternative to help cater the needs of society with\n 99m<\/jats:sup>\n Tc labeled PSMA inhibitor, which is very easily available and a cost effective solution for imaging prostate cancer workup.\n <\/jats:p>\n <\/jats:sec>\n \n Material and Method:<\/jats:title>\n \n A retrospective analysis was conducted on 39 patients who had undergone\n 99m<\/jats:sup>\n Tc-HYNIC-PSMA-11 study over a period of 6 months. The patients were further categorized based on spread of disease and divided in two categories: localized disease and oligometastatic disease. Imaging was done under Discovery NM\/CT 670 DR model SPECT\/CT. The planar and SPECT\/CT images were analyzed using Xeleris DR Functional imaging (Version 4.1) workstation under Q. Volumetric MI evolution for oncology software and maximum and mean standardized uptake value (SUV\n max<\/jats:sub>\n , SUV\n mean<\/jats:sub>\n ) were determined on skeletal and soft tissue regions for both the categories (localized and oligometastatic). Further, statistical analysis was conducted through an independent samples t-test to find the significance, if any.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n The biodistribution of\n 99m<\/jats:sup>\n Tc- HYNIC-PSMA-11 showed high uptake in parotid gland, submandibular gland, kidneys and urinary bladder, of which kidneys showed the highest uptake in all the scans. The SUV\n max<\/jats:sub>\n and SUV\n mean<\/jats:sub>\n comparison between localized and oligometastatic condition for various body regions did not show any statistically significant differences as indicted by the p-value.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n \n The biodistribution of\n 99m<\/jats:sup>\n Tc- HYNIC-PSMA-11 is similar to 68Ga-PSMA-11 scan, hence can be used as a cost-effective alternate for imaging overexpression of PSMA in case of prostate cancer patients.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijnm.ijnm_45_25","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:01:19Z","timestamp":1761926479000},"page":"269-277","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Biodistribution and Semiquantitative Analysis of 99mTc-HYNIC-PSMA-11in Prostate Cancer Patients: A Retrospective Study"],"prefix":"10.25259","volume":"40","author":[{"given":"Sachin","family":"Tayal","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritwik","family":"Sinha","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Homi Bhabha Cancer Hospital and Research Centre, Tata Medical Centre, New Chandigarh, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manikandan Marappagounder","family":"Venkatachalam","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Suresh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay Prakash","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manojkumar Ramsoorat","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uddeshya Narayan","family":"Jha","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Kalra","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Homi Bhabha Cancer Hospital and Research Centre, Tata Medical Centre, New Chandigarh, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"R1-20251130","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"R2-20251130","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R3-20251130","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"R4-20251130","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1148\/rg.2017170035","article-title":"Clinical PET imaging in prostate cancer","volume":"37","author":"Wallitt","year":"2017","journal-title":"Radiographics"},{"key":"R5-20251130","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.eururo.2015.10.008","article-title":"Association between RECIST changes and survival in patients with metastatic castration-resistant prostate cancer receiving docetaxel","volume":"69","author":"Sonpavde","year":"2016","journal-title":"Eur Urol"},{"key":"R6-20251130","doi-asserted-by":"crossref","first-page":"79S","DOI":"10.2967\/jnumed.115.170720","article-title":"The rise of PSMA ligands for diagnosis and therapy of prostate cancer","volume":"57","author":"Afshar-Oromieh","year":"2016","journal-title":"J Nucl Med"},{"key":"R7-20251130","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcb.10661","article-title":"Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer","volume":"91","author":"Ghosh","year":"2004","journal-title":"J Cell Biochem"},{"key":"R8-20251130","first-page":"634","article-title":"Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: Prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?","volume":"46","author":"Vallabhajosula","year":"2005","journal-title":"J Nucl Med"},{"key":"R9-20251130","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1200\/JCO.2005.05.160","article-title":"Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer","volume":"23","author":"Bander","year":"2005","journal-title":"J Clin Oncol"},{"key":"R10-20251130","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2967\/jnumed.112.104661","article-title":"Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer","volume":"53","author":"Cho","year":"2012","journal-title":"J Nucl Med"},{"key":"R11-20251130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-20251130","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","article-title":"The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: Biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions","volume":"56","author":"Afshar-Oromieh","year":"2015","journal-title":"J Nucl Med"},{"key":"R13-20251130","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1158\/1055-9965.EPI-13-0668","article-title":"Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer","volume":"22","author":"Kasperzyk","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R14-20251130","first-page":"1","article-title":"Diagnostic performance of 99mTc-HYNIC-PSMA SPECT\/ CT for biochemically recurrent prostate cancer after radical prostatectomy","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"R15-20251130","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/PAI.0000000000000110","article-title":"PSMA expression is highly homogenous in primary prostate cancer","volume":"23","author":"Tsourlakis","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R16-20251130","first-page":"241","article-title":"Prostate-specific membrane antigen as a target for cancer imaging and therapy","volume":"59","author":"Kiess","year":"2015","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R17-20251130","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.nucmedbio.2016.08.006","article-title":"Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer","volume":"43","author":"Pillai","year":"2016","journal-title":"Nucl Med Biol"},{"key":"R18-20251130","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.nucmedbio.2015.06.003","article-title":"A high-affinity [(18) F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer","volume":"42","author":"Ganguly","year":"2015","journal-title":"Nucl Med Biol"},{"key":"R19-20251130","doi-asserted-by":"crossref","first-page":"849","DOI":"10.7150\/thno.14744","article-title":"Towards personalized treatment of prostate cancer: PSMA I and T, a promising prostate-specific membrane antigen-targeted theranostic agent","volume":"6","author":"Chatalic","year":"2016","journal-title":"Theranostics"},{"key":"R20-20251130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1536012118776068","article-title":"PSMA theranostics: Current status and future directions","volume":"17","author":"Rahbar","year":"2018","journal-title":"Mol Imaging"},{"key":"R21-20251130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00259-017-3817-y","article-title":"Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617","volume":"45","author":"Kratochwil","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R22-20251130","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/pros.23444","article-title":"(99m) Tc-MIP-1404-SPECT\/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer","volume":"78","author":"Schmidkonz","year":"2018","journal-title":"Prostate"},{"key":"R23-20251130","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s12149-019-01400-6","article-title":"PSMA SPECT\/CT with (99m)Tc-MIP-1404 in biochemical recurrence of prostate cancer: Predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels","volume":"33","author":"Schmidkonz","year":"2019","journal-title":"Ann Nucl Med"},{"key":"R24-20251130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/RLU.0000000000001433","article-title":"First experience with SPECT\/CT using a 99mTc-labeled inhibitor for prostate-specific membrane antigen in patients with biochemical recurrence of prostate cancer","volume":"42","author":"Reinfelder","year":"2017","journal-title":"Clin Nucl Med"},{"key":"R25-20251130","first-page":"332","article-title":"Head to head comparison performance of (99m)Tc-EDDA\/HYNIC-iPSMA SPECT\/CT and (68)Ga-PSMA-11 PET\/CT a prospective study in biochemical recurrence prostate cancer patients","volume":"8","author":"Garc\u00eda-P\u00e9rez","year":"2018","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"R26-20251130","doi-asserted-by":"crossref","first-page":"541656","DOI":"10.1155\/2012\/541656","article-title":"Radiotherapy for oligometastases and oligo-recurrence of bone in prostate cancer","volume":"2012","author":"Tabata","year":"2012","journal-title":"Pulm Med"},{"key":"R27-20251130","first-page":"215","article-title":"Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer","volume":"2","author":"Ahmed","year":"2012","journal-title":"Front Oncol"},{"key":"R28-20251130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.clgc.2012.08.003","article-title":"Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: Deferring androgen deprivation therapy","volume":"11","author":"Berkovic","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"R29-20251130","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3109\/0284186X.2013.764010","article-title":"Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and\/or distant metastases","volume":"52","author":"Schick","year":"2013","journal-title":"Acta Oncol"},{"key":"R30-20251130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eururo.2015.07.004","article-title":"Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: A multi-institutional analysis","volume":"69","author":"Ost","year":"2016","journal-title":"Eur Urol"},{"key":"R31-20251130","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1748-717X-9-135","article-title":"Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence","volume":"9","author":"Decaestecker","year":"2014","journal-title":"Radiat Oncol"},{"key":"R32-20251130","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2967\/jnumed.114.140426","article-title":"99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: Pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer","volume":"55","author":"Vallabhajosula","year":"2014","journal-title":"J Nucl Med"},{"key":"R33-20251130","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid (6)(8)Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J Nucl Med"},{"key":"R34-20251130","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","article-title":"F-18 labelled PSMA-1007: Biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R35-20251130","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","article-title":"Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate Cancer","volume":"17","author":"Dietlein","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"R36-20251130","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2967\/jnumed.119.234898","article-title":"Intraindividual comparison of (18) F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer","volume":"61","author":"Dietlein","year":"2020","journal-title":"J Nucl Med"},{"key":"R37-20251130","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1097\/RLU.0000000000001273","article-title":"Intrapatient comparison of 111In-PSMA I and T SPECT\/CT and hybrid 68Ga-HBED-CC PSMA PET in patients with early recurrent prostate cancer","volume":"41","author":"Rauscher","year":"2016","journal-title":"Clin Nucl Med"},{"key":"R38-20251130","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4103\/1008-682X.192638","article-title":"Evaluation of 99mTc-labeled PSMA-SPECT\/CT imaging in prostate cancer patients who have undergone biochemical relapse","volume":"19","author":"Su","year":"2017","journal-title":"Asian J Androl"},{"key":"R39-20251130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2017.05.005","article-title":"(99m)Tc-labeled PSMA inhibitor: Biokinetics and radiation dosimetry in healthy subjects and imaging of prostate cancer tumors in patients","volume":"52","author":"Santos-Cuevas","year":"2017","journal-title":"Nucl Med Biol"},{"key":"R40-20251130","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/pros.23379","article-title":"Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT\/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET\/CT","volume":"77","author":"Lawal","year":"2017","journal-title":"Prostate"},{"key":"R41-20251130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2967\/jnumed.116.178939","article-title":"Preclinical evaluation and first patient application of 99mTc-PSMA-I and S for SPECT imaging and radioguided surgery in prostate cancer","volume":"58","author":"Robu","year":"2017","journal-title":"J Nucl Med"},{"key":"R42-20251130","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2967\/jnumed.117.200220","article-title":"Intraindividual comparison of (99m)Tc-methylene diphosphonate and prostate-specific membrane antigen ligand (99m) Tc-MIP-1427 in patients with osseous metastasized prostate cancer","volume":"59","author":"Rathke","year":"2018","journal-title":"J Nucl Med"},{"key":"R43-20251130","first-page":"1","article-title":"Direct comparison of (99m)Tc-PSMA SPECT\/CT and (68)Ga-PSMA PET\/CT in patients with prostate cancer","volume":"8","author":"Albalooshi","year":"2020","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"R44-20251130","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177) Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R45-20251130","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"R46-20251130","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"key":"R48-20251130","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1038\/s41598-020-61129-5","article-title":"Evaluation of radiation dosimetry of (99m)Tc-HYNIC-PSMA and imaging in prostate cancer","volume":"10","author":"Zhang\/;","year":"2020","journal-title":"Sci Rep"},{"key":"R49-20251130","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1097\/RLU.0000000000003410","article-title":"99mTc-PSMA SPECT\/CT versus 68Ga-PSMA PET\/CT in the evaluation of metastatic prostate cancer","volume":"46","author":"Fallahi","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R50-20251130","first-page":"1","article-title":"The efficacy of (99m)Tc-HYNIC-PSMA SPECT\/CT in detecting primary lesions and metastasis in newly diagnosed prostate cancer","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"}],"container-title":["Indian Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijnm.ijnm_45_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:38:33Z","timestamp":1779694713000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijnm.co.in\/biodistribution-and-semiquantitative-analysis-of-99mtc-hynic-psma-11in-prostate-cancer-patients-a-retrospective-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijnm.ijnm_45_25","relation":{},"ISSN":["0972-3919","0974-0244"],"issn-type":[{"value":"0972-3919","type":"print"},{"value":"0974-0244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2025-03-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}